Abstract：
Purpose: Vitiligo is an idiopathic depigmenting skin disorder. The study compares the efficacy of topical tacrolimus 0.1% with calcipotriol/betamethasone dipropionate in vitiligo patients receiving NB-UVB treatment.Materials and methods: Forty-one adult patients with generalized type vitiligo were recruited. Patients were assigned to phototherapy and then classified into either group one (20 patients), receiving calcipotriol/betamethasone dipropionate cream (D group), or group two (21 patients), receiving tacrolimus 0.1% ointment (T group). They were followed-up at 3 and 6 months.Results: The D group witnessed an increase in the repigmentation area from 35.4% in the third month to 54.7% in the sixth month (p = 0.001) and the T group from 32.2% to 45.6% (p = 0.011). However, the differences between the treatment groups were not statistically significant. Body sites demonstrated different levels of improvement ranging from the highest in the face to the lowest in the Hand & Feet with the other body sites in between. A negative correlation was identified between the duration since diagnosis and the response to D treatment (3 months: r = -0.612, p = 0.007; 6 months: r = -0.755, p = 0.001).Conclusions: Although both combinations are efficacious, they did not significantly differ in efficacy at three and six months follow-up points.Clinical trial registration: The study was registered at clinicaltrials.gov (NCT04440371).
摘要：
目的：白癜风是一种特发性皮肤色素脱失性疾病。该研究比较了接受NB-UVB治疗的白癜风患者局部使用0.1％他克莫司与卡泊三醇/二丙酸倍他米松的疗效。材料与方法：纳入41例成人广泛性白癜风患者。患者被分配到光疗，然后分为任何一组（20名患者），接受卡泊三醇/二丙酸倍他米松乳膏（D组），或第二组（21名患者），接受0.1%他克莫司软膏（T组）。随访3个月和6个月。结果：D组的色素沉着面积从第三个月的35.4％增加到第六个月的54.7％（p=0.001），T组的色素沉着面积从32.2％增加到45.6％（p=0.011）。然而,治疗组之间的差异无统计学意义.身体部位表现出不同程度的改善，从面部最高到手脚最低，其他身体部位介于两者之间。自诊断以来的持续时间与对D治疗的反应之间存在负相关（3个月：r=-0.612，p=0.007；6个月：r=-0.755，p=0.001）。结论：尽管两种组合都有效，在3个月和6个月随访时,两组患者的疗效无显著差异.临床试验注册：该研究在clinicaltrials.gov（NCT04440371）注册。
